Medicare GLP-1 Bridge Opens July at $50 Monthly Copay
CMS BALANCE Model Medicaid enrollment is open now. The Medicare GLP-1 Bridge starts July 1, covering Wegovy and Zepbound at $50/month for Part D enrollees.
May 21, 2026 · 3 min read
Two major changes to Medicare and Medicaid coverage of GLP-1 weight-loss drugs are taking effect this year. CMS's BALANCE Model has opened state Medicaid enrollment in May 2026, and a separate Medicare demonstration — the Medicare GLP-1 Bridge — launches July 1 with a $50/month copay for eligible Part D beneficiaries.
What happened
CMS formally announced the BALANCE Model (Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth) in January 2026. The model is a voluntary program through which CMS negotiates pricing and coverage terms with GLP-1 manufacturers on behalf of participating state Medicaid programs and Medicare Part D plan sponsors.
The rollout timeline:
| Program | Launch | Who it covers |
|---|---|---|
| BALANCE Model — Medicaid | May 2026 (rolling) | State Medicaid beneficiaries; states opt in |
| Medicare GLP-1 Bridge | July 1 – Dec 31, 2026 | Medicare Part D enrollees with obesity; $50 copay |
| BALANCE Model — Medicare Part D | January 2027 | Full Medicare Part D rollout |
The Medicare GLP-1 Bridge covers Wegovy (semaglutide 2.4 mg) and Zepbound (tirzepatide) for weight reduction. To qualify, Part D enrollees need a BMI of 35 or above — or BMI of 27 or above with clinical criteria. The bridge operates outside the standard Part D benefit structure during its six-month demonstration window.
Why it matters
Until this year, Medicare's coverage of obesity drugs was effectively blocked by a decades-old statutory restriction on Part D covering weight-loss medications. The FDA's cardiovascular approval of Wegovy in March 2024 opened a narrow pathway, and the BALANCE Model represents CMS's first structured, large-scale program to provide obesity drug coverage for Medicare and Medicaid beneficiaries.
For the approximately 26 million Medicare beneficiaries with obesity, the bridge program is the first time brand-name GLP-1 drugs for weight loss become broadly accessible — at a defined, capped out-of-pocket cost — outside of a diabetes diagnosis.
The model is voluntary. Drug manufacturers must agree to participate, and not all Part D plans are required to cover under the bridge. Whether coverage is available in practice depends on plan participation.
What to watch
The bridge program runs July 1 through December 31, 2026 — after which the full BALANCE Model is expected to replace it for Medicare Part D in January 2027. CMS is also monitoring uptake: if plan and manufacturer participation is low, the bridge may not meaningfully improve access in practice.
For Medicaid, only 13 states were covering GLP-1s for obesity before this program. The rolling enrollment (through December 2026) gives states flexibility to join, but political and budget pressures mean not all states are expected to participate quickly.
Beneficiaries who think they may qualify should contact their Medicare Part D plan directly to confirm whether Wegovy or Zepbound is covered under the bridge program — plan participation varies.
Sources
- BALANCE Model — CMS Innovation Center
- KFF: What to Know About the BALANCE Model
- CMS press release — BALANCE Model launch
Does Medicare cover semaglutide? — the full coverage picture for Part D and Part B Semaglutide guide — how Wegovy and Ozempic work Tirzepatide guide — how Zepbound and Mounjaro work
Sources